Journal Description
Marine Drugs
Marine Drugs
is the leading, peer-reviewed, open access journal on the research, development, and production of biologically and therapeutically active compounds from the sea. Marine Drugs is published monthly online by MDPI. Australia New Zealand Marine Biotechnology Society (ANZMBS) is affiliated with Marine Drugs and its members receive a discount on article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
- Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor:
4.9 (2023);
5-Year Impact Factor:
5.2 (2023)
Latest Articles
Protection of Tight Junctional Complexes between hCMEC/D3 Cells by Deep-Sea Fibrinolytic Compound FGFC1
Mar. Drugs 2024, 22(8), 341; https://doi.org/10.3390/md22080341 - 26 Jul 2024
Abstract
Tight junctional complexes (TJCs) between cerebral microvascular endothelial cells (CMECs) are essential parts of the blood–brain barrier (BBB), whose regulation closely correlates to the BBB’s integrity and function. hCMEC/D3 is the typical cell line used to imitate and investigate the barrier function of
[...] Read more.
Tight junctional complexes (TJCs) between cerebral microvascular endothelial cells (CMECs) are essential parts of the blood–brain barrier (BBB), whose regulation closely correlates to the BBB’s integrity and function. hCMEC/D3 is the typical cell line used to imitate and investigate the barrier function of the BBB via the construction of an in vitro model. This study aims to investigate the protective effect of the deep-sea-derived fibrinolytic compound FGFC1 against H2O2-induced dysfunction of TJCs and to elucidate the underlying mechanism. The barrier function was shown to decline following exposure to 1 mM H2O2 in an in vitro model of hCMEC/D3 cells, with a decreasing temperature-corrected transendothelial electrical resistance (tcTEER) value. The decrease in the tcTEER value was significantly inhibited by 80 or 100 µM FGFC1, which suggested it efficiently protected the barrier integrity, allowing it to maintain its function against the H2O2-induced dysfunction. According to immunofluorescence microscopy (IFM) and quantitative real-time polymerase chain reaction (qRT-PCR), compared to the H2O2-treated group, 80~100 µM FGFC1 enhanced the expression of claudin-5 (CLDN-5) and VE-cadherin (VE-cad). And this enhancement was indicated to be mainly achieved by both up-regulation of CLDN-5 and inhibition of the down-regulation by H2O2 of VE-cad at the transcriptional level. Supported by FGFC1’s molecular docking to these proteins with reasonable binding energy, FGFC1 was proved to exert a positive effect on TJCs’ barrier function in hCMEC/D3 cells via targeting CLDN-5 and VE-cad. This is the first report on the protection against H2O2-induced barrier dysfunction by FGFC1 in addition to its thrombolytic effect. With CLDN-5 and VE-cad as the potential target proteins of FGFC1, this study provides evidence at the cellular and molecular levels for FGFC1’s reducing the risk of bleeding transformation following its application in thrombolytic therapy for cerebral thrombosis.
Full article
(This article belongs to the Special Issue Bioactive Natural Products from the Deep-Sea-Sourced Microbes)
►
Show Figures
Open AccessArticle
Evaluation of Antioxidant Activity of Residue from Bioethanol Production Using Seaweed Biomass
by
In-Yung Sunwoo, Hyunjin Cho, Taeho Kim, Eun-Jeong Koh and Gwi-Taek Jeong
Mar. Drugs 2024, 22(8), 340; https://doi.org/10.3390/md22080340 - 26 Jul 2024
Abstract
This study explores the potential of producing bioethanol from seaweed biomass and reusing the residues as antioxidant compounds. Various types of seaweed, including red (Gelidium amansii, Gloiopeltis furcata, Pyropia tenera), brown (Saccharina japonica, Undaria pinnatifida, Ascophyllum
[...] Read more.
This study explores the potential of producing bioethanol from seaweed biomass and reusing the residues as antioxidant compounds. Various types of seaweed, including red (Gelidium amansii, Gloiopeltis furcata, Pyropia tenera), brown (Saccharina japonica, Undaria pinnatifida, Ascophyllum nodosum), and green species (Ulva intestinalis, Ulva prolifera, Codium fragile), were pretreated with dilute acid and enzymes and subsequently processed to produce bioethanol with Saccharomyces cerevisiae BY4741. Ethanol production followed the utilization of sugars, resulting in the highest yields from red algae > brown algae > green algae due to their high carbohydrate content. The residual biomass was extracted with water, ethanol, or methanol to evaluate its antioxidant activity. Among the nine seaweeds, the A. nodosum bioethanol residue extract (BRE) showed the highest antioxidant activity regarding the 2,2-diphenyl-1-picrylhydrazyl (DPPH) activity, ferric reducing antioxidant power (FRAP), and reactive oxygen species (ROS) inhibition of H2O2-treated RAW 264.7 cells. These by-products can be valorized, contributing to a more sustainable and economically viable biorefinery process. This dual approach not only enhances the utilization of marine resources but also supports the development of high-value bioproducts.
Full article
(This article belongs to the Special Issue Fermentation Processes for Obtaining Marine Bioactive Products)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00340/article_deploy/html/images/marinedrugs-22-00340-g001-550.jpg?1721997847)
Figure 1
Open AccessArticle
From Sea Sponge to Clinical Trials: Starting the Journey of the Novel Compound PM742
by
Patricia G. Cruz, Rogelio Fernández, Raquel Rodríguez-Acebes, Marta Martínez-Díez, Gema Santamaría-Núñez, Marta Pérez and Carmen Cuevas
Mar. Drugs 2024, 22(8), 339; https://doi.org/10.3390/md22080339 - 26 Jul 2024
Abstract
PM742 (1), a new chemical entity, has been isolated from the sponge Discodermia du Bocage collected in the Pacific Ocean. This compound showed strong in vitro cytotoxicity against several human tumor cell lines as well as a tubulin depolymerization mechanism of
[...] Read more.
PM742 (1), a new chemical entity, has been isolated from the sponge Discodermia du Bocage collected in the Pacific Ocean. This compound showed strong in vitro cytotoxicity against several human tumor cell lines as well as a tubulin depolymerization mechanism of action, which led us to conduct an extensive Structure-Activity-Relationship study through the synthesis of different analogs. As a result, a derivatively named PM534 (2) is currently in its first human Phase I clinical trial. Herein, we present a comprehensive review of the isolation, structural elucidation, and antitumor activities of the parent compound PM742.
Full article
(This article belongs to the Special Issue From Seaside to Bedside: Dedicated to Professor José María Fernández Sousa-Faro)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00339/article_deploy/html/images/marinedrugs-22-00339-ag-550.jpg?1721988359)
Graphical abstract
Open AccessReview
Modulation of Apoptotic, Cell Cycle, DNA Repair, and Senescence Pathways by Marine Algae Peptides in Cancer Therapy
by
Visuddho Visuddho, Princella Halim, Helen Helen, Adi Muradi Muhar, Muhammad Iqhrammullah, Nelly Mayulu, Reggie Surya, Raymond Rubianto Tjandrawinata, Rosy Iara Maciel Azambuja Ribeiro, Trina Ekawati Tallei, Nurpudji Astuti Taslim, Bonglee Kim, Rony Abdi Syahputra and Fahrul Nurkolis
Mar. Drugs 2024, 22(8), 338; https://doi.org/10.3390/md22080338 - 25 Jul 2024
Abstract
Marine algae, encompassing both macroalgae and microalgae, have emerged as a promising and prolific source of bioactive compounds with potent anticancer properties. Despite their significant therapeutic potential, the clinical application of these peptides is hindered by challenges such as poor bioavailability and susceptibility
[...] Read more.
Marine algae, encompassing both macroalgae and microalgae, have emerged as a promising and prolific source of bioactive compounds with potent anticancer properties. Despite their significant therapeutic potential, the clinical application of these peptides is hindered by challenges such as poor bioavailability and susceptibility to enzymatic degradation. To overcome these limitations, innovative delivery systems, particularly nanocarriers, have been explored. Nanocarriers, including liposomes, nanoparticles, and micelles, have demonstrated remarkable efficacy in enhancing the stability, solubility, and bioavailability of marine algal peptides, ensuring controlled release and prolonged therapeutic effects. Marine algal peptides encapsulated in nanocarriers significantly enhance bioavailability, ensuring more efficient absorption and utilization in the body. Preclinical studies have shown promising results, indicating that nanocarrier-based delivery systems can significantly improve the pharmacokinetic profiles and therapeutic outcomes of marine algal peptides. This review delves into the diverse anticancer mechanisms of marine algal peptides, which include inducing apoptosis, disrupting cell cycle progression, and inhibiting angiogenesis. Further research focused on optimizing nanocarrier formulations, conducting comprehensive clinical trials, and continued exploration of marine algal peptides holds great promise for developing innovative, effective, and sustainable cancer therapies.
Full article
(This article belongs to the Special Issue Discovery of Marine-Derived Anticancer Agents)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00338/article_deploy/html/images/marinedrugs-22-00338-g001-550.jpg?1721995314)
Figure 1
Open AccessArticle
C-Phycoerythrin Prevents Chronic Kidney Disease-Induced Systemic Arterial Hypertension, Avoiding Oxidative Stress and Vascular Dysfunction in Remanent Functional Kidney
by
Oscar Iván Florencio-Santiago, Vanesa Blas-Valdivia, José Iván Serrano-Contreras, Placido Rojas-Franco, Gerardo Norberto Escalona-Cardoso, Norma Paniagua-Castro, Margarita Franco-Colin and Edgar Cano-Europa
Mar. Drugs 2024, 22(8), 337; https://doi.org/10.3390/md22080337 - 25 Jul 2024
Abstract
Chronic kidney disease (CKD) is a burden in low- and middle-income countries, and a late diagnosis with systemic arterial hypertension (SAH) is the major complication of CKD. C-phycoerythrin (CPE) is a bioactive compound derived from Phormidium persicinum that presents anti-inflammatory and antioxidant effects
[...] Read more.
Chronic kidney disease (CKD) is a burden in low- and middle-income countries, and a late diagnosis with systemic arterial hypertension (SAH) is the major complication of CKD. C-phycoerythrin (CPE) is a bioactive compound derived from Phormidium persicinum that presents anti-inflammatory and antioxidant effects in vitro and nephroprotective effects in vivo. In the current study, we determine the antihypertensive effect of CPE in a 5/6 nephrectomy-induced CKD model using twenty normotensives male Wistar rats, grouped into four groups (n = 5): sham; sham + CPE; 5/6 nephrectomy (NFx); and NFx + CPE. Treatment started a week post-surgery and continued for five weeks, with weekly hemodynamic evaluations. Following treatment, renal function, oxidative stress, and the expression of vascular dysfunction markers were assessed. The renal function analysis revealed CKD hyperfiltration, and the hemodynamic evaluation showed that SAH developed at the third week. AT1R upregulation and AT2R downregulation together with Mas1/p-Akt/p-eNOS axis were also observed. CPE treatment mitigated renal damage, preserved renal function, and prevented SAH with the modulation of the vasodilative AT1R, AT2R, and Mas1/pAKT/peNOS axis. This result reveals that CPE prevented CKD progression to SAH by avoiding oxidative stress and vascular dysfunction in the kidneys.
Full article
(This article belongs to the Special Issue Application of Marine Nature Products to Reduce Oxidative Stress)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00337/article_deploy/html/images/marinedrugs-22-00337-ag-550.jpg?1721909186)
Graphical abstract
Open AccessReview
Marine Algae and Deriving Biomolecules for the Management of Inflammatory Bowel Diseases: Potential Clinical Therapeutics to Decrease Gut Inflammatory and Oxidative Stress Markers?
by
Alberto Repici, Ahmed Hasan, Anna Paola Capra, Sarah Adriana Scuderi, Irene Paterniti, Michela Campolo, Alessio Ardizzone and Emanuela Esposito
Mar. Drugs 2024, 22(8), 336; https://doi.org/10.3390/md22080336 - 25 Jul 2024
Abstract
The term “inflammatory bowel disease” (IBD) describes a class of relapse-remitting conditions that affect the gastrointestinal (GI) tract. Among these, Crohn’s disease (CD) and ulcerative colitis (UC) are two of the most globally prevalent and debilitating conditions. Several articles have brought attention to
[...] Read more.
The term “inflammatory bowel disease” (IBD) describes a class of relapse-remitting conditions that affect the gastrointestinal (GI) tract. Among these, Crohn’s disease (CD) and ulcerative colitis (UC) are two of the most globally prevalent and debilitating conditions. Several articles have brought attention to the significant role that inflammation and oxidative stress cooperatively play in the development of IBD, offering a different viewpoint both on its etiopathogenesis and on strategies for the effective treatment of these conditions. Marine ecosystems may be a significant source of physiologically active substances, supporting the search for new potential clinical therapeutics. Based on this evidence, this review aims to comprehensively evaluate the activity of marine algae and deriving biomolecules in decreasing pathological features of CD and UC. To match this purpose, a deep search of the literature on PubMed (MEDLINE) and Google Scholar was performed to highlight primary biological mechanisms, the modulation of inflammatory and oxidative stress biochemical parameters, and potential clinical benefits deriving from marine species. From our findings, both macroalgae and microalgae have shown potential as therapeutic solutions for IBD due to their bioactive compounds and their anti-inflammatory and antioxidant activities which are capable of modulating markers such as cytokines, the NF-κB pathway, reactive oxidative and nitrosative species (ROS and RNS), trefoil factor 3 (TFF3), lactoferrin, SIRT1, etc. However, while we found promising preclinical evidence, more extensive and long-term clinical studies are necessary to establish the efficacy and safety of marine algae for IBD treatment.
Full article
(This article belongs to the Special Issue Marine Natural Products with Immunomodulatory Activity)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00336/article_deploy/html/images/marinedrugs-22-00336-ag-550.jpg?1721985617)
Graphical abstract
Open AccessArticle
Stichoposide C and Rhizochalin as Potential Aquaglyceroporin Modulators
by
Ji Woo Im, Ju Hyun Lim, Valentin A. Stonik, Jong-Young Kwak, Songwan Jin, Minkook Son and Hae-Rahn Bae
Mar. Drugs 2024, 22(8), 335; https://doi.org/10.3390/md22080335 - 25 Jul 2024
Abstract
Aquaporins (AQPs) are a family of integral membrane proteins that selectively transport water and glycerol across the cell membrane. Because AQPs are involved in a wide range of physiological functions and pathophysiological conditions, AQP-based therapeutics may have the broad potential for clinical utility,
[...] Read more.
Aquaporins (AQPs) are a family of integral membrane proteins that selectively transport water and glycerol across the cell membrane. Because AQPs are involved in a wide range of physiological functions and pathophysiological conditions, AQP-based therapeutics may have the broad potential for clinical utility, including for disorders of water and energy balance. However, AQP modulators have not yet been developed as suitable candidates for clinical applications. In this study, to identify potential modulators of AQPs, we screened 31 natural products by measuring the water and glycerol permeability of mouse erythrocyte membranes using a stopped-flow light scattering method. None of the tested natural compounds substantially affected the osmotic water permeability. However, several compounds considerably affected the glycerol permeability. Stichoposide C increased the glycerol permeability of mouse erythrocyte membranes, whereas rhizochalin decreased it at nanomolar concentrations. Immunohistochemistry revealed that AQP7 was the main aquaglyceroporin in mouse erythrocyte membranes. We further verified the effects of stichoposide C and rhizochalin on aquaglyceroporins using human AQP3-expressing keratinocyte cells. Stichoposide C, but not stichoposide D, increased AQP3-mediated transepithelial glycerol transport, whereas the peracetyl aglycon of rhizochalin was the most potent inhibitor of glycerol transport among the tested rhizochalin derivatives. Collectively, stichoposide C and the peracetyl aglycon of rhizochalin might function as modulators of AQP3 and AQP7, and suggests the possibility of these natural products as potential drug candidates for aquaglyceroporin modulators.
Full article
(This article belongs to the Special Issue Target Identification of Marine Natural Products)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00335/article_deploy/html/images/marinedrugs-22-00335-g001-550.jpg?1721880946)
Figure 1
Open AccessArticle
Cyanotoxins in Epipelic and Epiphytic Cyanobacteria from a Hypersaline Coastal Lagoon, an Environmental Hazard in Climate Warming Times and a Potential Source of New Compounds
by
Yerai Gómez-Leyva, Alejandro Torrecillas and Marina Aboal
Mar. Drugs 2024, 22(8), 334; https://doi.org/10.3390/md22080334 - 24 Jul 2024
Abstract
Cyanobacterial biodiversity and potential toxicity in coastal lagoons have barely been studied despite these transitional water systems being very important in conservation and for the preservation of economic resources. Most of these transitional systems have been affected by eutrophication, and climate change will
[...] Read more.
Cyanobacterial biodiversity and potential toxicity in coastal lagoons have barely been studied despite these transitional water systems being very important in conservation and for the preservation of economic resources. Most of these transitional systems have been affected by eutrophication, and climate change will severely affect them by promoting cyanobacteria growth, especially in Mediterranean areas. This study aims to characterize the diversity of epipelic and epiphytic cyanobacteria species in a Mediterranean coastal lagoon and their potential for toxins production (microcystins and saxitoxins). Strains were isolated and genetically identified. Toxins were extracted and quantified by LC/MS-MS. All the taxa belong to the former Oscillatoriales. The presence of Nodosilinea and Toxifilum is reported for the first time for Spanish waters, but Pseudanabaena, Phormidium, Geitlerinema and Synechococcus also formed part of benthic mats. All the strains contained Microcystin-YR (MC-YR), but saxitoxin (STX) was present only in the extracts of Nodosilinea and Pseudanabena. MC-LY, MC-LW and [D-Asp3] MC-LR were detected in the extracts of Synechococcus and MC-LF in Toxifilum, but at concentrations that did not permit quantification. Toxins production by epipelic and epiphytic strains in coastal lagoons may represent a hazard, but also an opportunity to obtain potentially interesting compounds that should be further studied.
Full article
(This article belongs to the Special Issue Emerging Toxins Accumulation in Shellfish)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00334/article_deploy/html/images/marinedrugs-22-00334-ag-550.jpg?1721916032)
Graphical abstract
Open AccessArticle
Jellyfish Venom Peptides Targeting Human Potassium Channels Identified through Ligand Screening: Morphometric and Molecular Identification of the Species and Antibiotic Potential
by
Edirisinghe Arachchige Hashini Wasthala Edirisinghe, Buddhima Nirmani Athukorala, Minoli Perera, Bothunga Arachchige Shamali Dilhara Abeywardana, Polgahawattage Sachini Tarushika Sigera, Pasindu Eranga, Kavindu Dinuhara Theekshana, Mohamad Boudjelal, Rizwan Ali and Dinithi Champika Peiris
Mar. Drugs 2024, 22(8), 333; https://doi.org/10.3390/md22080333 - 24 Jul 2024
Abstract
The relative lack of marine venom could be attributed to the difficulty in dealing with venomous marine animals. Moreover, the venom of marine animals consists of various bioactive molecules, many of which are proteins with unique properties. In this study, we investigated the
[...] Read more.
The relative lack of marine venom could be attributed to the difficulty in dealing with venomous marine animals. Moreover, the venom of marine animals consists of various bioactive molecules, many of which are proteins with unique properties. In this study, we investigated the potential toxic proteins of jellyfish collected for ligand screening to understand the mechanism of the toxic effects of jellyfish. Since taxonomic identification is problematic due to the lack of proper keys, we conducted morphological and molecular mitochondrial DNA sequencing from COI and ITS regions. The venom extract from nematocysts found along the bell margins was used for protein characterization using SDS-gel electrophoresis and nano-liquid chromatography-tandem mass spectrometry. Ligand screening for the most potent toxin and antibacterial and cytotoxicity assays were carried out. The phylogenetic tree showed distinct clustering from other Catostylus sp. The proteomic analysis revealed venom with many bioactive proteins. Only 13 venom proteins were identified with molecular weights ranging from 4318 to 184,923 Da, exhibiting the venom’s complexity. The overall toxin protein composition of Catostylus sp. venom was dominated by potassium channel toxin alpha-KTx. Molecular docking of toxin alpha-KTx 1.13 revealed high specificity towards the human voltage-gated potassium channel Kv3 with a high fitness score and a minimum energy barrier of −17.9 kcal/mol. Disc diffusion and cytotoxicity assays revealed potent antibacterial activity against Klebsiella pneumoniae with no cytotoxicity. Further studies on detailed characterization and therapeutic potentials are warranted.
Full article
(This article belongs to the Special Issue Toxins as Marine-Based Drug Discovery, 2nd Edition)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00333/article_deploy/html/images/marinedrugs-22-00333-ag-550.jpg?1721889024)
Graphical abstract
Open AccessCommunication
Induction of Three New Secondary Metabolites by the Co-Culture of Endophytic Fungi Phomopsis asparagi DHS-48 and Phomopsis sp. DHS-11 Isolated from the Chinese Mangrove Plant Rhizophora mangle
by
Jingwan Wu, Jingjing Ye, Juren Cen, Yuanjie Chen and Jing Xu
Mar. Drugs 2024, 22(8), 332; https://doi.org/10.3390/md22080332 - 24 Jul 2024
Abstract
Co-cultivation is a powerful emerging tool for awakening biosynthetic gene clusters (BGCs) that remain transcriptionally silent under artificial culture conditions. It has recently been used increasingly extensively to study natural interactions and discover new bioactive metabolites. As a part of our project aiming
[...] Read more.
Co-cultivation is a powerful emerging tool for awakening biosynthetic gene clusters (BGCs) that remain transcriptionally silent under artificial culture conditions. It has recently been used increasingly extensively to study natural interactions and discover new bioactive metabolites. As a part of our project aiming at the discovery of structurally novel and biologically active natural products from mangrove endophytic fungi, an established co-culture of a strain of Phomopsis asparagi DHS-48 with another Phomopsis genus fungus DHS-11, both endophytes in mangrove Rhizophora mangle, proved to be very efficient to induce the production of new metabolites as well as to increase the yields of respective target metabolites. A detailed chemical investigation of the minor metabolites produced by the co-culture of these two titled fungal strains led to the isolation of six alkaloids (1–6), two sterols (7, 8), and six polyketides (9–14). In addition, all the compounds except 8 and 10, as well as three new metabolites phomopyrazine (1), phomosterol C (7), and phomopyrone E (9), were not present in discrete fungal cultures and only detected in the co-cultures. The structures were elucidated on the basis of spectroscopic analysis, and the absolute configurations were assumed by electronic circular dichroism (ECD) calculations. Subsequently, the cytotoxic, immunosuppressive, and acetylcholinesterase inhibitory properties of all the isolated metabolites were determined in vitro. Compound 8 exhibited moderate inhibitory activity against ConA-induced T and LPS-induced B murine splenic lymphocytes, with IC50 values of 35.75 ± 1.09 and 47.65 ± 1.21 µM, respectively.
Full article
(This article belongs to the Section Marine Pharmacology)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00332/article_deploy/html/images/marinedrugs-22-00332-ag-550.jpg?1721794036)
Graphical abstract
Open AccessArticle
Macrolactin X, a Macrolactin Antibiotic from Marine Bacillus subtilis sp.18
by
Yao Xu, Yihao Song, Yaodong Ning, Song Li, Yingxin Qu, Binghua Jiao and Xiaoling Lu
Mar. Drugs 2024, 22(8), 331; https://doi.org/10.3390/md22080331 - 23 Jul 2024
Abstract
Two new compounds, macrolactin X (1) and dihydroxylaureonitol (2), together with nine known compounds (3–11) were isolated from the marine Bacillus subtilis sp.18 by the OSMAC strategy. These compounds were evaluated for antibacterial activity against
[...] Read more.
Two new compounds, macrolactin X (1) and dihydroxylaureonitol (2), together with nine known compounds (3–11) were isolated from the marine Bacillus subtilis sp.18 by the OSMAC strategy. These compounds were evaluated for antibacterial activity against six tested microorganisms. Compounds 1–5 and 7–10 showed varied antibacterial activity, with the minimum inhibitory concentration (MIC) ranging from 3 to 12 μg/mL. Macrolactin X (1) was found to possess superior antibacterial activity, especially exhibiting significant effectiveness against Enterococcus faecalis. The antibacterial activity mechanism against E. faecalis was investigated. The mechanism may disrupt bacterial cell membrane integrity and permeability, and also inhibit the expression of genes associated with bacterial energy metabolism, as established by the experiments concerning cell membrane potential, SDS-PAGE electrophoresis, cell membrane integrity, and key gene expressions. This study offers valuable insights and serves as a theoretical foundation for the future development of macrolactins as antibacterial precursors.
Full article
(This article belongs to the Special Issue Bio-Active Products from Mangrove Ecosystems 2.0)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00331/article_deploy/html/images/marinedrugs-22-00331-g001-550.jpg?1721886719)
Figure 1
Open AccessArticle
Brown Algae Ecklonia cava Extract Modulates Adipogenesis and Browning in 3T3-L1 Preadipocytes through HO-1/Nrf2 Signaling
by
Indyaswan T. Suryaningtyas, Dae-Sung Lee and Jae-Young Je
Mar. Drugs 2024, 22(8), 330; https://doi.org/10.3390/md22080330 - 23 Jul 2024
Abstract
This study explores the anti-obesity effects of the ethyl acetate extract of Ecklonia cava (EC-ETAC) on 3T3-L1 preadipocytes, focusing on its impact on adipogenesis, lipolysis, and adipose browning via the HO-1/Nrf2 pathway. Western blot analysis revealed that EC-ETAC significantly inhibited adipogenic transcription factors
[...] Read more.
This study explores the anti-obesity effects of the ethyl acetate extract of Ecklonia cava (EC-ETAC) on 3T3-L1 preadipocytes, focusing on its impact on adipogenesis, lipolysis, and adipose browning via the HO-1/Nrf2 pathway. Western blot analysis revealed that EC-ETAC significantly inhibited adipogenic transcription factors (PPARγ, C/EBPα, SREBP-1) and lipogenesis-related proteins (FAS, LPL). Concurrently, EC-ETAC enhanced lipolytic markers (p-AMPK, p-HSL) and adipose browning-related proteins (UCP-1, PGC-1α), indicating its role in promoting lipolysis and adipose browning. The inhibition of HO-1 by zinc protoporphyrin (ZnPP) significantly reversed these effects, underscoring the critical role of HO-1 in mediating the anti-obesity properties of EC-ETAC. Additionally, fluorescence measurements and Oil Red O staining confirmed the reduction of lipid accumulation and oxidative stress upon EC-ETAC treatment. These findings suggest that EC-ETAC exerts its anti-obesity effects by modulating the HO-1/Nrf2 pathway, which is crucial for regulating adipogenesis, lipolysis, and adipose browning. This study highlights the potential of EC-ETAC as a natural therapeutic agent for obesity management and supports further research into its clinical applications. By targeting the HO-1/Nrf2 pathway, EC-ETAC could offer a novel approach to enhancing energy expenditure and reducing fat mass, thereby improving metabolic health.
Full article
(This article belongs to the Special Issue High-Value Algae Products)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00330/article_deploy/html/images/marinedrugs-22-00330-g001-550.jpg?1721725042)
Figure 1
Open AccessReview
Genetic Engineering and Innovative Cultivation Strategies for Enhancing the Lutein Production in Microalgae
by
Bert Coleman, Elke Vereecke, Katrijn Van Laere, Lucie Novoveska and Johan Robbens
Mar. Drugs 2024, 22(8), 329; https://doi.org/10.3390/md22080329 - 23 Jul 2024
Abstract
Carotenoids, with their diverse biological activities and potential pharmaceutical applications, have garnered significant attention as essential nutraceuticals. Microalgae, as natural producers of these bioactive compounds, offer a promising avenue for sustainable and cost-effective carotenoid production. Despite the ability to cultivate microalgae for its
[...] Read more.
Carotenoids, with their diverse biological activities and potential pharmaceutical applications, have garnered significant attention as essential nutraceuticals. Microalgae, as natural producers of these bioactive compounds, offer a promising avenue for sustainable and cost-effective carotenoid production. Despite the ability to cultivate microalgae for its high-value carotenoids with health benefits, only astaxanthin and β-carotene are produced on a commercial scale by Haematococcus pluvialis and Dunaliella salina, respectively. This review explores recent advancements in genetic engineering and cultivation strategies to enhance the production of lutein by microalgae. Techniques such as random mutagenesis, genetic engineering, including CRISPR technology and multi-omics approaches, are discussed in detail for their impact on improving lutein production. Innovative cultivation strategies are compared, highlighting their advantages and challenges. The paper concludes by identifying future research directions, challenges, and proposing strategies for the continued advancement of cost-effective and genetically engineered microalgal carotenoids for pharmaceutical applications.
Full article
(This article belongs to the Special Issue Algal Cultivation for Obtaining High-Value Products)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00329/article_deploy/html/images/marinedrugs-22-00329-ag-550.jpg?1721718567)
Graphical abstract
Open AccessArticle
Combining In Vitro, In Vivo, and Network Pharmacology Assays to Identify Targets and Molecular Mechanisms of Spirulina-Derived Biomolecules against Breast Cancer
by
Soha Osama Hassanin, Amany Mohammed Mohmmed Hegab, Reham Hassan Mekky, Mohamed Adel Said, Mona G. Khalil, Alaaeldin Ahmed Hamza and Amr Amin
Mar. Drugs 2024, 22(7), 328; https://doi.org/10.3390/md22070328 - 22 Jul 2024
Abstract
The current research employed an animal model of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary gland carcinogenesis. The estrogen receptor-positive human breast adenocarcinoma cell line (MCF-7) was used for in vitro analysis. This was combined with a network pharmacology-based approach to assess the anticancer properties of Spirulina
[...] Read more.
The current research employed an animal model of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary gland carcinogenesis. The estrogen receptor-positive human breast adenocarcinoma cell line (MCF-7) was used for in vitro analysis. This was combined with a network pharmacology-based approach to assess the anticancer properties of Spirulina (SP) extract and understand its molecular mechanisms. The results showed that the administration of 1 g/kg of SP increased the antioxidant activity by raising levels of catalase (CAT) and superoxide dismutase (SOD), while decreasing the levels of malonaldehyde (MDA) and protein carbonyl. A histological examination revealed reduced tumor occurrence, decreased estrogen receptor expression, suppressed cell proliferation, and promoted apoptosis in SP protected animals. In addition, SP disrupted the G2/M phase of the MCF-7 cell cycle, inducing apoptosis and reactive oxygen species (ROS) accumulation. It also enhanced intrinsic apoptosis in MCF-7 cells by upregulating cytochrome c, Bax, caspase-8, caspase-9, and caspase-7 proteins, while downregulating Bcl-2 production. The main compounds identified in the LC-MS/MS study of SP were 7-hydroxycoumarin derivatives of cinnamic acid, hinokinin, valeric acid, and α-linolenic acid. These substances specifically targeted three important proteins: ERK1/2 MAPK, PI3K-protein kinase B (AKT), and the epidermal growth factor receptor (EGFR). Network analysis and molecular docking indicated a significant binding affinity between SP and these proteins. This was verified by Western blot analysis that revealed decreased protein levels of p-EGFR, p-ERK1/2, and p-AKT following SP administration. SP was finally reported to suppress MCF-7 cell growth and induce apoptosis by modulating the PI3K/AKT/EGFR and MAPK signaling pathways suggesting EGFR as a potential target of SP in breast cancer (BC) treatment.
Full article
(This article belongs to the Special Issue Discovery of Marine-Derived Anticancer Agents)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00328/article_deploy/html/images/marinedrugs-22-00328-ag-550.jpg?1721798331)
Graphical abstract
Open AccessReview
Seaweeds as Source of Bioactive Pigments with Neuroprotective and/or Anti-Neurodegenerative Activities: Astaxanthin and Fucoxanthin
by
Estela Guardado Yordi, Amaury Pérez Martínez, Matteo Radice, Laura Scalvenzi, Reinier Abreu-Naranjo, Eugenio Uriarte, Lourdes Santana and Maria Joao Matos
Mar. Drugs 2024, 22(7), 327; https://doi.org/10.3390/md22070327 - 22 Jul 2024
Abstract
The marine kingdom is an important source of a huge variety of scaffolds inspiring the design of new drugs. The complex molecules found in the oceans present a great challenge to organic and medicinal chemists. However, the wide variety of biological activities they
[...] Read more.
The marine kingdom is an important source of a huge variety of scaffolds inspiring the design of new drugs. The complex molecules found in the oceans present a great challenge to organic and medicinal chemists. However, the wide variety of biological activities they can display is worth the effort. In this article, we present an overview of different seaweeds as potential sources of bioactive pigments with activity against neurodegenerative diseases, especially due to their neuroprotective effects. Along with a broad introduction to seaweed as a source of bioactive pigments, this review is especially focused on astaxanthin and fucoxanthin as potential neuroprotective and/or anti-neurodegenerative agents. PubMed and SciFinder were used as the main sources to search and select the most relevant scientific articles within the field.
Full article
(This article belongs to the Special Issue Synthetic Chemistry in Marine Drug Discovery: Challenges and Opportunities)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00327/article_deploy/html/images/marinedrugs-22-00327-g001-550.jpg?1721636843)
Figure 1
Open AccessArticle
Molecular Dynamics Simulation Reveal the Structure–Activity Relationships of Kainoid Synthases
by
Zeyu Fan, Xinhao Li, Ruoyu Jiang, Jinqian Li, Fangyu Cao, Mingjuan Sun and Lianghua Wang
Mar. Drugs 2024, 22(7), 326; https://doi.org/10.3390/md22070326 - 22 Jul 2024
Abstract
Kainoid synthases are key enzymes in the biosynthesis of kainoids. Kainoids, as represented by DA and KA, are a class of naturally occurring non-protein amino acids with strong neurotransmitter activity in the mammalian central nervous system. Marine algae kainoid synthases include PnDabC from
[...] Read more.
Kainoid synthases are key enzymes in the biosynthesis of kainoids. Kainoids, as represented by DA and KA, are a class of naturally occurring non-protein amino acids with strong neurotransmitter activity in the mammalian central nervous system. Marine algae kainoid synthases include PnDabC from diatoms, which synthesizes domoic acid (DA), and DsKabC and GfKabC from red algae, which synthesize kainic acid (KA). Elucidation of the catalytic mechanism of kainoid synthases is of great significance for the rational design of better biocatalysts to promote the industrial production of kainoids for use in new drugs. Through modeling, molecular docking, and molecular dynamics simulations, we investigated the conformational dynamics of kainoid synthases. We found that the kainoid synthase complexes showed different stability in the simulation, and the binding and catalytic processes showed significant conformational transformations of kainoid synthase. The residues involved in specific interactions with the substrate contributed to the binding energy throughout the simulation process. Binding energy, the relaxed active pocket, electrostatic potential energy of the active pocket, the number and rotation of aromatic residues interacting with substrates during catalysis, and the number and frequency of hydrogen bonds between the individual functional groups revealed the structure–activity relationships and affected the degree of promiscuity of kainoid synthases. Our research enriches the understanding of the conformational dynamics of kainoid synthases and has potential guiding significance for their rational design.
Full article
(This article belongs to the Special Issue Biosynthesis, Metabolism, Pharmacology and Biological Receptors of Marine Algal Toxins)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00326/article_deploy/html/images/marinedrugs-22-00326-g001-550.jpg?1721982313)
Figure 1
Open AccessArticle
Proteomics Analysis of the Protective Effect of Polydeoxyribonucleotide Extracted from Sea Cucumber (Apostichopus japonicus) Sperm in a Hydrogen Peroxide-Induced RAW264.7 Cell Injury Model
by
Zhiqiang Shu, Yizhi Ji, Fang Liu, Yuexin Jing, Chunna Jiao, Yue Li, Yunping Zhao, Gongming Wang and Jian Zhang
Mar. Drugs 2024, 22(7), 325; https://doi.org/10.3390/md22070325 - 21 Jul 2024
Abstract
Sea cucumber viscera contain various naturally occurring active substances, but they are often underutilized during sea cucumber processing. Polydeoxyribonucleotide (PDRN) is an adenosine A2A receptor agonist that activates the A2A receptor to produce various biological effects. Currently, most studies on the
[...] Read more.
Sea cucumber viscera contain various naturally occurring active substances, but they are often underutilized during sea cucumber processing. Polydeoxyribonucleotide (PDRN) is an adenosine A2A receptor agonist that activates the A2A receptor to produce various biological effects. Currently, most studies on the activity of PDRN have focused on its anti-inflammatory, anti-apoptotic, and tissue repair properties, yet relatively few studies have investigated its antioxidant activity. In this study, we reported for the first time that PDRN was extracted from the sperm of Apostichopus japonicus (AJS-PDRN), and we evaluated its antioxidant activity using 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), and hydroxyl radical scavenging assays. An in vitro injury model was established using H2O2-induced oxidative damage in RAW264.7 cells, and we investigated the protective effect of AJS-PDRN on these cells. Additionally, we explored the potential mechanism by which AJS-PDRN protects RAW264.7 cells from damage using iTRAQ proteomics analysis. The results showed that AJS-PDRN possessed excellent antioxidant activity and could significantly scavenge DPPH, ABTS, and hydroxyl radicals. In vitro antioxidant assays demonstrated that AJS-PDRN was cytoprotective and significantly enhanced the antioxidant capacity of RAW264.7 cells. The results of GO enrichment and KEGG pathway analysis indicate that the protective effects of AJS-PDRN pretreatment on RAW264.7 cells are primarily achieved through the regulation of immune and inflammatory responses, modulation of the extracellular matrix and signal transduction pathways, promotion of membrane repair, and enhancement of cellular antioxidant capacity. The results of a protein–protein interaction (PPI) network analysis indicate that AJS-PDRN reduces cellular oxidative damage by upregulating the expression of intracellular selenoprotein family members. In summary, our findings reveal that AJS-PDRN mitigates H2O2-induced oxidative damage through multiple pathways, underscoring its significant potential in the prevention and treatment of diseases caused by oxidative stress.
Full article
(This article belongs to the Special Issue Marine Anti-inflammatory and Antioxidant Agents 4.0)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00325/article_deploy/html/images/marinedrugs-22-00325-g001-550.jpg?1721547304)
Figure 1
Open AccessArticle
Aspergillusidone G Potentiates the Anti-Inflammatory Effects of Polaprezinc in LPS-Induced BV2 Microglia: A Bioinformatics and Experimental Study
by
Fangfang Ban, Longjian Zhou, Zhiyou Yang, Yayue Liu and Yi Zhang
Mar. Drugs 2024, 22(7), 324; https://doi.org/10.3390/md22070324 - 19 Jul 2024
Abstract
Neuroinflammation is one of the main mechanisms involved in the progression of neurodegenerative diseases (NDs), and microglial activation is the main feature of neuroinflammation. Polaprezinc (Pol), a chelator of L-carnosine and zinc, is widely used as a clinical drug for gastric ulcers. However,
[...] Read more.
Neuroinflammation is one of the main mechanisms involved in the progression of neurodegenerative diseases (NDs), and microglial activation is the main feature of neuroinflammation. Polaprezinc (Pol), a chelator of L-carnosine and zinc, is widely used as a clinical drug for gastric ulcers. However, its potential effects on NDs remain unexplored. In LPS-induced BV-2 microglia, we found that Pol reduced the generation of NO and ROS and revealed inhibited expression of iNOS, COX-2, and inflammatory factors such as IL-6, TNF-α, and 1L-1β by Pol using qRT-PCR and Western blotting. These effects were found to be associated with the suppression of the NF-κB signaling pathway. Moreover, we evaluated the potential synergistic effects of aspergillusidone G (Asp G) when combined with Pol. Remarkably, co-treatment with low doses of Asp G enhanced the NO inhibition by Pol from approximately 30% to 80% in LPS-induced BV2 microglia, indicating a synergistic anti-inflammatory effect. A bioinformatics analysis suggested that the synergistic mechanism of Asp G and Pol might be attributed to several targets, including NFκB1, NRF2, ABL1, TLR4, and PPARα. These findings highlight the anti-neuroinflammatory properties of Pol and its enhanced efficacy when combined with Asp G, proposing a novel therapeutic strategy for managing neuroinflammation in NDs.
Full article
(This article belongs to the Special Issue Marine Alkaloids: Sources, Discovery, Diversity, and Bioactivities)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00324/article_deploy/html/images/marinedrugs-22-00324-ag-550.jpg?1721395144)
Graphical abstract
Open AccessArticle
From Sea to Science: Coral Aquaculture for Sustainable Anticancer Drug Development
by
Hung-Yu Lin, Tsen-Ni Tsai, Kai-Cheng Hsu, Yu-Ming Hsu, Lin-Chien Chiang, Mohamed El-Shazly, Ken-Ming Chang, Yu-Hsuan Lin, Shang-Yi Tu, Tony Eight Lin, Ying-Chi Du, Yi-Chang Liu and Mei-Chin Lu
Mar. Drugs 2024, 22(7), 323; https://doi.org/10.3390/md22070323 - 19 Jul 2024
Abstract
Marine natural products offer immense potential for drug development, but the limited supply of marine organisms poses a significant challenge. Establishing aquaculture presents a sustainable solution for this challenge by facilitating the mass production of active ingredients while reducing our reliance on wild
[...] Read more.
Marine natural products offer immense potential for drug development, but the limited supply of marine organisms poses a significant challenge. Establishing aquaculture presents a sustainable solution for this challenge by facilitating the mass production of active ingredients while reducing our reliance on wild populations and harm to local environments. To fully utilize aquaculture as a source of biologically active products, a cell-free system was established to target molecular components with protein-modulating activity, including topoisomerase II, HDAC, and tubulin polymerization, using extracts from aquaculture corals. Subsequent in vitro studies were performed, including MTT assays, flow cytometry, confocal microscopy, and Western blotting, along with in vivo xenograft models, to verify the efficacy of the active extracts and further elucidate their cytotoxic mechanisms. Regulatory proteins were clarified using NGS and gene modification techniques. Molecular docking and SwissADME assays were performed to evaluate the drug-likeness and pharmacokinetic and medicinal chemistry-related properties of the small molecules. The extract from Lobophytum crassum (LCE) demonstrated potent broad-spectrum activity, exhibiting significant inhibition of tubulin polymerization, and showed low IC50 values against prostate cancer cells. Flow cytometry and Western blotting assays revealed that LCE induced apoptosis, as evidenced by the increased expression of apoptotic protein-cleaved caspase-3 and the populations of early and late apoptotic cells. In the xenograft tumor experiments, LCE significantly suppressed tumor growth and reduced the tumor volume (PC3: 43.9%; Du145: 49.2%) and weight (PC3: 48.8%; Du145: 7.8%). Additionally, LCE inhibited prostate cancer cell migration, and invasion upregulated the epithelial marker E-cadherin and suppressed EMT-related proteins. Furthermore, LCE effectively attenuated TGF-β-induced EMT in PC3 and Du145 cells. Bioactivity-guided fractionation and SwissADME validation confirmed that LCE’s main component, 13-acetoxysarcocrassolide (13-AC), holds greater potential for the development of anticancer drugs.
Full article
(This article belongs to the Special Issue Marine Natural Products as Anticancer Agents 3.0)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00323/article_deploy/html/images/marinedrugs-22-00323-g001-550.jpg?1721383403)
Figure 1
Open AccessArticle
Systematical Investigation on Anti-Fatigue Function and Underlying Mechanism of High Fischer Ratio Oligopeptides from Antarctic Krill on Exercise-Induced Fatigue in Mice
by
Sha-Yi Mao, Shi-Kun Suo, Yu-Mei Wang, Chang-Feng Chi and Bin Wang
Mar. Drugs 2024, 22(7), 322; https://doi.org/10.3390/md22070322 - 19 Jul 2024
Abstract
►▼
Show Figures
High Fischer ratio oligopeptides (HFOs) have a variety of biological activities, but their mechanisms of action for anti-fatigue are less systematically studied at present. This study aimed to systematically evaluate the anti-fatigue efficacy of HFOs from Antarctic krill (HFOs-AK) and explore its mechanism
[...] Read more.
High Fischer ratio oligopeptides (HFOs) have a variety of biological activities, but their mechanisms of action for anti-fatigue are less systematically studied at present. This study aimed to systematically evaluate the anti-fatigue efficacy of HFOs from Antarctic krill (HFOs-AK) and explore its mechanism of action through establishing the fatigue model of endurance swimming in mice. Therefore, according to the comparison with the endurance swimming model group, HFOs-AK were able to dose-dependently prolong the endurance swimming time, reduce the levels of the metabolites (lactic acid, blood urea nitrogen, and blood ammonia), increase the content of blood glucose, muscle glycogen, and liver glycogen, reduce lactate dehydrogenase and creatine kinase extravasation, and protect muscle tissue from damage in the endurance swimming mice. HFOs-AK were shown to enhance Na+-K+-ATPase and Ca2+-Mg2+-ATPase activities and increase ATP content in muscle tissue. Meanwhile, HFOs-AK also showed significantly antioxidant ability by increasing the activities of superoxide dismutase and glutathione peroxidase in the liver and decreasing the level of malondialdehyde. Further studies showed that HFOs-AK could regulate the body’s energy metabolism and thus exert its anti-fatigue effects by activating the AMPK signaling pathway and up-regulating the expression of p-AMPK and PGC-α proteins. Therefore, HFOs-AK can be used as an auxiliary functional dietary molecules to exert its good anti-fatigue activity and be applied to anti-fatigue functional foods.
Full article
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00322/article_deploy/html/images/marinedrugs-22-00322-g001-550.jpg?1721381890)
Figure 1
![Marine Drugs marinedrugs-logo](https://pub.mdpi-res.com/img/journals/marinedrugs-logo.png?8600e93ff98dbf14)
Journal Menu
► ▼ Journal Menu-
- Marine Drugs Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Vol. 22 (2024)
- Vol. 21 (2023)
- Vol. 20 (2022)
- Vol. 19 (2021)
- Vol. 18 (2020)
- Vol. 17 (2019)
- Vol. 16 (2018)
- Vol. 15 (2017)
- Vol. 14 (2016)
- Vol. 13 (2015)
- Vol. 12 (2014)
- Vol. 11 (2013)
- Vol. 10 (2012)
- Vol. 9 (2011)
- Vol. 8 (2010)
- Vol. 7 (2009)
- Vol. 6 (2008)
- Vol. 5 (2007)
- Vol. 4 (2006)
- Vol. 3 (2005)
- Vol. 2 (2004)
- Vol. 1 (2003)
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Applied Biosciences, JMSE, Marine Drugs, Toxins, Molecules
Marine Biotoxins and Bioactive Marine Natural Products
Topic Editors: Naomasa Oshiro, Ana Gago-Martínez, Takeshi Tsumuraya, Tsuyoshi IkeharaDeadline: 31 August 2024
Topic in
Molecules, Pharmaceutics, Antibiotics, Microorganisms, Biomolecules, Marine Drugs, Polymers, IJMS
Antimicrobial Agents and Nanomaterials
Topic Editors: Sandra Pinto, Vasco D. B. BonifácioDeadline: 30 September 2024
Topic in
Biomolecules, IJMS, Molecules, Sci. Pharm., Marine Drugs, Plants
Antioxidant Activity of Natural Products—2nd Edition
Topic Editors: José Virgílio Santulhão Pinela, Maria Inês Moreira Figueiredo Dias, Carla Susana Correia Pereira, Alexandra PlácidoDeadline: 30 September 2025
![loading...](https://pub.mdpi-res.com/img/loading_circle.gif?9a82694213036313?1721979229)
Conferences
Special Issues
Special Issue in
Marine Drugs
Bioactive Polysaccharides from Seaweeds
Guest Editors: Faiez Hentati, Laurent VandanjonDeadline: 31 July 2024
Special Issue in
Marine Drugs
Sustainable Circular Bioeconomy Approaches for the Biotechnological Development of Marine-Derived Products
Guest Editors: Susana P. Gaudencio, Ana Rotter, Cristiana A. V. TorresDeadline: 31 August 2024
Special Issue in
Marine Drugs
Value-Added Products from Marine Fishes
Guest Editors: Helena Maria Lourenço, Sónia PedroDeadline: 15 September 2024
Special Issue in
Marine Drugs
Metabolites in Marine Planktonic Organisms
Guest Editors: Valeria Di Dato, Ida OreficeDeadline: 30 September 2024
Topical Collections
Topical Collection in
Marine Drugs
Microalgal Active Biomolecules
Collection Editor: Cédric Delattre
Topical Collection in
Marine Drugs
Marine Compounds and Cancer
Collection Editors: Friedemann Honecker, Sergey A. Dyshlovoy
Topical Collection in
Marine Drugs
Papers from “Sino–Italian Symposium on Bioactive Natural Products”
Collection Editors: Orazio Taglialatela-Scafati, Hong Wang